Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 4:33 PM ET

Biotechnology

Company Overview of Aimmune Therapeutics, Inc.

Executive Profile

Stephen George Dilly M.B.B.S, Ph.D.

Chief Executive Officer, President and Director, Aimmune Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 5 different industries.

See Board Relationships
55$469,681
As of Fiscal Year 2014

Background

Dr. Stephen George Dilly, M.B.B.S, Ph.D. has been the Chief Executive Officer of Aimmune Therapeutics, Inc. (formerly Allergen Research Corporation) since April 2014 and serves as its President. Dr. Dilly serves as Strategic Advisor at Physic Ventures, LLC. Dr. Dilly served as the Chief Executive officer of PhotoThera, Inc. from January 2012 to December 2012 and served as its President. Dr. Dilly served as Chief Executive Officer and President at APT Pharmaceutical LLC ...

Corporate Headquarters

8000 Marina Boulevard
Brisbane, California 94005

United States

Phone: 650-614-5220
Fax: 650-616-0075

Board Members Memberships

2010-Present
Director and Chairman of Clinical Review Committee
2013-Present
Chief Executive Officer, President and Director

Education

PhD 1988
University Of London
Bachelor's Degree 1982
University Of London

Other Affiliations

Annual Compensation

Salary$262,500
Bonus$125,000
Total Annual Compensation$387,500

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$412,500
Total Short Term Compensation$387,500
Total Calculated Compensation$469,681
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Pierre-Henri Benhamou M.D.Co-Founder, Chairman and Chief Executive Officer
DBV Technologies S.A.
$427.7K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aimmune Therapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.